RecruitingPhase 1

A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight

A Phase 1, Investigator- and Participant-Blinded, Placebo-Controlled, Randomized, Multiple-Dose Study to Evaluate the Gastric Emptying Delay, Pharmacokinetics, Safety, and Tolerability of Eloralintide in Participants With Obesity or Overweight

Lead sponsor

Eli Lilly and Company

Asset

Eloralintide

Subcutaneous · Amylin analog

Listed sites

Recruiting sites

Estimated enrollment

Study population

Obesity / overweight

Eligibility highlights

•BMI 27-45•Healthy volunteers

Primary endpoints

•Acetaminophen AUC•Acetaminophen Cmax (Cₘₐₓ)•Acetaminophen Time to Cmax (tₘₐₓ)

Registered trial locations

Locations reported to ClinicalTrials.gov for this trial snapshot. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT07738614

Org study ID27759

Secondary IDJ3R-MC-YDAPEli Lilly and Company

Timeline

Milestones

Study first posted2026-07-31actual

Study start2026-07-31actual

Last update posted2026-08-20actual

Primary completion2026-12estimated (month precision)

Study completion2026-12estimated (month precision)

Assets

Investigational agents

Eloralintide

Who this study enrolls

Obesity / overweight

Who can enroll

Minimum age18 Years

Maximum age65 Years

SexAll

Healthy volunteersAccepted

Inclusion criteria

•Have overweight or obesity, but are otherwise overtly healthy.

•Have a body mass index (BMI) within the range of 27.0 to 45.0 kilograms (kg)/square meter (m²), inclusive.

•Have had a stable body weight, with less than 5 percent (%) change during the 3-month period prior to screening.

Exclusion criteria

•Have been diagnosed with Type 1 or Type 2 diabetes mellitus, or have either of the following at screening

-A fasting plasma glucose concentration greater than or equal to 126 milligrams (mg)/deciliter (dL) or 7.0 millimoles (mmol)/liter (L), or

-Hemoglobin A1C (HbA1c) greater than or equal to 6.5% or 48 mmol/mole (mol).

•Have a history or presence of psychiatric disorders, including a history of major depressive disorder or severe psychiatric disorders such as schizophrenia, and bipolar disorder, within the last 2 years.

•Have received a glucagon-like peptide-1 (GLP-1) receptor agonist, glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonist, or GIP/GLP-1/glucagon receptor agonist within 60 days or 5 half-lives, whichever is longer, prior to screening.

•Are in the judgment of the investigator, actively suicidal or deemed to be at significant risk for suicide.

Endpoints (5)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Other (unclassified)

Safety / tolerability / PK

2 endpoints

Primary/protocol endpoint

Acetaminophen Area Under the Concentration Versus Time Curve (AUC)

Time frame:Baseline to Day 65

concentration, descriptive

Secondary/protocol endpoint

Eloralintide AUC

Time frame:Baseline to Day 106

concentration, descriptive

Other (unclassified)

3 endpoints

Primary/protocol endpoint/low confidence

Acetaminophen Maximum Observed Concentration (Cₘₐₓ)

Time frame:Baseline to Day 65

concentration, descriptive

Primary/protocol endpoint/low confidence

Acetaminophen Time to Maximum Observed Drug Concentration (tₘₐₓ)

Time frame:Baseline to Day 65

time to event, event

Secondary/protocol endpoint/low confidence

Eloralintide Cₘₐₓ

Time frame:Baseline to Day 106

descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateNovember 5, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the November 5, 2026 snapshot.